On the evening of April 19, Shenzhen Jingfeng Medical Technology Co., Ltd. (referred to as "Jingfeng Medical") submitted the application materials for listing A1, with Morgan Stanley, China International Capital Corporation and Citigroup as co-sponsors, according to documents filed by the Hong Kong Stock Exchange on April 20. According to the prospectus, Jingfeng Medical is the world's leading and fast-growing surgical robot company dedicated to designing, developing, manufacturing and commercializing surgical robots. According to Frost Sullivan, the company has launched key clinical trials of porous and single-hole endoscopic surgery robots, which is the first in China and one of the only two companies in the world. At present, the company has completed the design and main research and development of fine front porous endoscopic surgery robot MP1000 and fine front single hole endoscopic surgery robot SP1000. Both MP1000 and SP1000 are qualified to conduct the rapid examination of innovative medical devices by the State Drug Administration through the green channel. MP1000 is the core product of the company, and SP1000 is the key product. MP1000 completed a registered clinical trial for urology surgery in December 2021. The clinical results show that MP1000 performs well, with an overall success rate of 100%. The effectiveness and safety shown in the head-to-head comparison is not inferior to that of the world's leading surgical robot Leonardo da Vinci surgery system. The company is the only Chinese company to include advanced T4 cancer in critical clinical trials of urology in China. Clinical trials of MP1000 for gynecological surgery began in December 2021, and patients are expected to be completed in the second quarter of 2022. Clinical trials of MP1000 in general surgery and thoracic surgery will also begin in January 2022. As a supplement to MP1000, SP1000 is widely used in gynecology, urology, general surgery, thoracic surgery and head and neck surgery because of its advantages such as small incision, rapid recovery and short hospital stay.